Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction.

Ramshaw H, Xu X, Jaehne EJ, McCarthy P, Greenberg Z, Saleh E, McClure B, Woodcock J, Kabbara S, Wiszniak S, Wang TY, Parish C, van den Buuse M, Baune BT, Lopez A, Schwarz Q.

Transl Psychiatry. 2013 Dec 3;3:e327. doi: 10.1038/tp.2013.99.

2.

14-3-3ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disorders.

Xu X, Jaehne EJ, Greenberg Z, McCarthy P, Saleh E, Parish CL, Camera D, Heng J, Haas M, Baune BT, Ratnayake U, van den Buuse M, Lopez AF, Ramshaw HS, Schwarz Q.

Sci Rep. 2015 Jul 24;5:12434. doi: 10.1038/srep12434.

3.

Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice.

Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B, Martres MP.

Neuropharmacology. 2007 Jun;52(7):1496-508. Epub 2007 Feb 24.

PMID:
17433376
4.

In-vivo administration of clozapine affects behaviour but does not reverse dendritic spine deficits in the 14-3-3ζ KO mouse model of schizophrenia-like disorders.

Jaehne EJ, Ramshaw H, Xu X, Saleh E, Clark SR, Schubert KO, Lopez A, Schwarz Q, Baune BT.

Pharmacol Biochem Behav. 2015 Nov;138:1-8. doi: 10.1016/j.pbb.2015.09.006. Epub 2015 Sep 10.

PMID:
26363310
5.

Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine.

Sotnikova TD, Budygin EA, Jones SR, Dykstra LA, Caron MG, Gainetdinov RR.

J Neurochem. 2004 Oct;91(2):362-73.

6.

mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, Galli A.

J Neurosci. 2015 Jun 10;35(23):8843-54. doi: 10.1523/JNEUROSCI.0887-15.2015.

7.

Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors.

Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies DL.

J Neurochem. 2016 Oct;139(1):134-48. doi: 10.1111/jnc.13734. Epub 2016 Aug 15.

8.

Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

Hall FS, Itokawa K, Schmitt A, Moessner R, Sora I, Lesch KP, Uhl GR.

Neuropharmacology. 2014 Jan;76 Pt A:146-55. doi: 10.1016/j.neuropharm.2013.07.031. Epub 2013 Aug 24.

9.

Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice.

Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A, Shippenberg T, Wang JB.

Neuropsychopharmacology. 2007 Aug;32(8):1774-82. Epub 2007 Jan 3.

10.

Regulation of Tyrosine Hydroxylase Expression and Phosphorylation in Dopamine Transporter-Deficient Mice.

Salvatore MF, Calipari ES, Jones SR.

ACS Chem Neurosci. 2016 Jul 20;7(7):941-51. doi: 10.1021/acschemneuro.6b00064. Epub 2016 May 10.

11.

Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.

Patel J, Mooslehner KA, Chan PM, Emson PC, Stamford JA.

J Neurochem. 2003 May;85(4):898-910.

12.

The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters in vivo responses to psychostimulants.

Mergy MA, Gowrishankar R, Gresch PJ, Gantz SC, Williams J, Davis GL, Wheeler CA, Stanwood GD, Hahn MK, Blakely RD.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4779-88. doi: 10.1073/pnas.1417294111. Epub 2014 Oct 20.

13.

Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs.

Ardayfio PA, Leung A, Park J, Hwang DY, Moran-Gates T, Choi YK, Carlezon WA Jr, Tarazi FI, Kim KS.

Neuroscience. 2010 Mar 17;166(2):391-6. doi: 10.1016/j.neuroscience.2009.12.033. Epub 2009 Dec 22.

14.

Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout.

Hall FS, Sora I, Hen R, Uhl GR.

PLoS One. 2014 Dec 16;9(12):e115009. doi: 10.1371/journal.pone.0115009. eCollection 2014.

15.

PRONOUNCED HYPERACTIVITY, COGNITIVE DYSFUNCTIONS AND BDNF DYSREGULATION IN DOPAMINE TRANSPORTER KNOCKOUT RATS.

Leo D, Sukhanov I, Zoratto F, Illiano P, Caffino L, Sanna F, Messa G, Emanuele M, Esposito A, Dorofeikova M, Budygin EA, Mus L, Efimova EE, Niello M, Espinoza S, Sotnikova TD, Hoener MC, Laviola G, Fumagalli F, Adriani W, Gainetdinov RR.

J Neurosci. 2018 Jan 18. pii: 1931-17. doi: 10.1523/JNEUROSCI.1931-17.2018. [Epub ahead of print]

PMID:
29348190
16.

Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.

Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B.

Biol Psychiatry. 2006 Mar 15;59(6):508-15. Epub 2005 Sep 30.

PMID:
16199010
17.

Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo.

Hewett J, Johanson P, Sharma N, Standaert D, Balcioglu A.

J Neurochem. 2010 Apr;113(1):228-35. doi: 10.1111/j.1471-4159.2010.06590.x. Epub 2010 Feb 2.

18.

Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice.

Wong P, Chang CC, Marx CE, Caron MG, Wetsel WC, Zhang X.

PLoS One. 2012;7(12):e51455. doi: 10.1371/journal.pone.0051455. Epub 2012 Dec 11.

19.

Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice.

Klejbor I, Myers JM, Hausknecht K, Corso TD, Gambino AS, Morys J, Maher PA, Hard R, Richards J, Stachowiak EK, Stachowiak MK.

J Neurochem. 2006 Jun;97(5):1243-58. Epub 2006 Mar 8.

20.

Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice.

Chen R, Furman CA, Zhang M, Kim MN, Gereau RW 4th, Leitges M, Gnegy ME.

J Pharmacol Exp Ther. 2009 Mar;328(3):912-20. doi: 10.1124/jpet.108.147959. Epub 2008 Dec 19.

Supplemental Content

Support Center